Business UpdateApr 23, 2026, 06:16 PM
Agomab Extends Cash Runway to H1 2029; Key Clinical Milestones Ahead
AI Summary
Agomab Therapeutics reported €116.5 million in cash and investments at year-end 2025, bolstered by $208 million from its February 2026 IPO, extending its cash runway into the first half of 2029. The company is on track to initiate a Phase 2b study for Ontunisertib in FSCD and a Phase 2 study for AGMB-447 in IPF during the second half of 2026, following positive regulatory interactions. Topline data from the Ontunisertib OLE study and AGMB-447 Phase 1b IPF cohort are also anticipated in H2 2026.
Key Highlights
- Cash & investments: €116.5M at Dec 31, 2025.
- IPO gross proceeds: $208M in Feb 2026.
- Cash runway: Expected into H1 2029.
- Ontunisertib Phase 2b FSCD study: On track for H2 2026.
- AGMB-447 Phase 2 IPF study: On track for H2 2026.